Skip to main content
SpringerLink
Log in

Cyclophosphamide and Etoposide for Non-Small Cell and Small Cell Lung Cancer

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral chemotherapeutic regimens with limited toxicity are desirable in that quality of life can be maintained and clinic/hospital visits minimised during therapy. We have investigated the use of extended courses of oral cyclophosphamide and oral etoposide for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A 14-day course of oral combination chemotherapy every 28 days resulted in a 12% response rate and a median survival of 6 months (1-year survival, 26%) in stage IV NSCLC. This regimen could not be intensified with carboplatin because of synergistic granulocytopenia. A 14-day course every 28 days resulted in a 40% response rate and a median survival of 7 months in poor-prognosis extensive-disease SCLC. Pharmacodynamic modelling revealed that the granulocyte nadir could be predicted from a single plasma etoposide level drawn on the second day of therapy, potentially allowing dose adjustment during the treatment cycle. Oral chemotherapy remains a promising route for the treatment of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10

    Article  PubMed  CAS  Google Scholar 

  2. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–40

    PubMed  CAS  Google Scholar 

  3. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374–7

    PubMed  CAS  Google Scholar 

  4. Dombernowsky P, Nissen NI. Combination chemotherapy with 4′ demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Eur J Cancer 1976; 12: 181–8

    Article  PubMed  CAS  Google Scholar 

  5. Estapé J, Cirera L, Millá A, et al. VP 16-213 and cyclophosphamide in advanced breast cancer. Cancer Chemother Pharmacol 1983; 10: 154–7

    Article  PubMed  Google Scholar 

  6. Estapé J, Daniels M, Viñolas N, et al. Combination chemotherapy with oral etoposide plus intravenous cyclophosphamide in liver metastases of breast cancer. Am J Clin Oncol 1990; 13: 98–100

    Article  PubMed  Google Scholar 

  7. Estapé J, Millá A, Agusti A, et al. VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1. Cancer 1979; 43: 72–7

    Article  PubMed  Google Scholar 

  8. Estapé J, Millá A, Agusti A, et al. VP-16 plus cyclophosphamide in the treatment of advanced lung cancer. Cancer 1983; 51: 385–9

    Article  PubMed  Google Scholar 

  9. Maulard-Durdux C, Dufour B, Hennequin C, et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77: 1144–8

    Article  PubMed  CAS  Google Scholar 

  10. Grunberg SM, Crowley J, Livingston R, et al. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 1598–1601

    PubMed  CAS  Google Scholar 

  11. Grunberg SM, Burris H III, Livingston R. The price of success. J Clin Oncol 1995; 13: 797–8

    PubMed  CAS  Google Scholar 

  12. Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; 2: 83–8

    CAS  Google Scholar 

  13. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin’s lymphoma. Am JPediatr Hematol Oncol 1993; 15: 99–104

    Article  CAS  Google Scholar 

  14. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia [review]. Cancer 1991; 68: 600–4

    CAS  Google Scholar 

  15. Loehrer PJ, Rynard S, Ansari R, et al. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer 1992; 69: 669–73

    Article  PubMed  Google Scholar 

  16. Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540–6

    PubMed  Google Scholar 

  17. Rudolph A, Einhorn L, Wampler G, et al. Cytoxan, adriamycin and etoposide (CAE) versus cytoxan, adriamycin and vincristine in the treatment of small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1983; 2: 192A

    Google Scholar 

  18. Grunberg SM, Valentine J, Zackon I, et al. Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer. Invest New Drugs 1996; 13: 333–5

    Article  PubMed  CAS  Google Scholar 

  19. Grunberg SM, Rector D, Hande K, et al. Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A Southwest Oncology Group clinical and pharmacokinetic study. Lung Cancer 1997; 18 Suppl. 1: 24–5

    Google Scholar 

  20. Carney DN, Grogan L, Smit EF, et al. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17 Suppl. 2: 49–53

    PubMed  CAS  Google Scholar 

  21. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577–80

    Article  PubMed  CAS  Google Scholar 

  22. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996; 348: 563–6

    CAS  Google Scholar 

  23. Pfeiffer P, Rytter C, Madsen EL, et al. Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomised comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 1892–3

    Article  PubMed  CAS  Google Scholar 

  24. Tebbutt NC, Snyder RD, Burns WI. An analysis of the outcomes of treatment of small cell lung cancer in the elderly. Aust NZ J Med 1997; 27: 160–4

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology Unit, University of Vermont College of Medicine, Fletcher Allen Health Care, 111 Colchester Avenue, Patrick 534, Burlington, VT, 05401, USA

    Steven M. Grunberg

Authors
  1. Steven M. Grunberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grunberg, S.M. Cyclophosphamide and Etoposide for Non-Small Cell and Small Cell Lung Cancer. Drugs 58 (Suppl 3), 11–15 (1999). https://doi.org/10.2165/00003495-199958003-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00002

Keywords

Search

Navigation